Clinical Trial

A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)

Recruiting
View on ClinicalTrials.gov →
Summary
This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-102-12C in the participants with GPC3-positive advanced hepatocellular carcinoma who previously received adequate but uneffective systemic standard treatments.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-25.
Status change: Not Yet Recruiting → Recruiting 2026-01-19
Trial Details
NCT Number NCT07039201
Lead Sponsor Zhejiang University
Collaborators: Cells & Genes Biotech
Conditions Advanced Hepatocellular Carcinoma (HCC)
Enrollment 12 participants
Start Date 2025-06-28
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-22